Trial Profile
A Multi-center, Study Investigating a New, Oral Growth Hormone Secretagogue (GHS)(AEZS 130, Formerly ARD-07) as a Growth Hormone (GH) Stimulation Test in Terms of Safety and Efficacy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Macimorelin (Primary)
- Indications Growth disorders
- Focus Diagnostic use; Registrational
- Sponsors AEterna Zentaris Inc; Ardana plc
- 06 Nov 2013 New trial record
- 05 Nov 2013 Data from this trial have been included in an NDA submitted to the FDA for the use of macimorelin in the diagnosis of adult growth hormone deficiency, according to an Aeterna Zentaris media release.
- 12 Jul 2011 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.